A detailed history of China Universal Asset Management Co., Ltd. transactions in Immunocore Holdings PLC stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 7,433 shares of IMCR stock, worth $210,056. This represents 0.03% of its overall portfolio holdings.

Number of Shares
7,433
Previous 4,380 69.7%
Holding current value
$210,056
Previous $148,000 56.08%
% of portfolio
0.03%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$30.06 - $41.49 $91,773 - $126,668
3,053 Added 69.7%
7,433 $231,000
Q2 2024

Jul 19, 2024

SELL
$33.78 - $63.75 $75,700 - $142,863
-2,241 Reduced 33.85%
4,380 $148,000
Q1 2024

Apr 29, 2024

BUY
$60.14 - $75.36 $163,640 - $205,054
2,721 Added 69.77%
6,621 $430,000
Q4 2023

May 21, 2024

SELL
$42.85 - $69.5 $116,594 - $189,109
-2,721 Reduced 41.1%
3,900 $266,000
Q4 2023

Jan 23, 2024

BUY
$42.85 - $69.5 $131,292 - $212,948
3,064 Added 366.51%
3,900 $266,000
Q3 2023

May 21, 2024

BUY
$49.5 - $66.6 $21,087 - $28,371
426 Added 103.9%
836 $43,000
Q3 2023

Oct 30, 2023

BUY
$49.5 - $66.6 $21,087 - $28,371
426 Added 103.9%
836 $43,000
Q2 2023

May 21, 2024

BUY
$48.54 - $61.64 $291 - $369
6 Added 1.49%
410 $24,000
Q2 2023

Jul 27, 2023

BUY
$48.54 - $61.64 $291 - $369
6 Added 1.49%
410 $25,000
Q1 2023

May 21, 2024

BUY
$46.12 - $65.71 $6,549 - $9,330
142 Added 54.2%
404 $19,000
Q1 2023

Apr 27, 2023

BUY
$46.12 - $65.71 $6,549 - $9,330
142 Added 54.2%
404 $20,000
Q4 2022

May 21, 2024

SELL
$45.51 - $65.08 $289,398 - $413,843
-6,359 Reduced 96.04%
262 $14,000
Q4 2022

Jan 31, 2023

BUY
$45.51 - $65.08 $11,923 - $17,050
262 New
262 $15,000

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.24B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.